Cinacalcet Use and the Risk of Gastrointestinal (GI) Bleeding Among Hemodialysis Patients with Secondary Hyperparathyroidism (SHPT) in DOPPS

First published: 09/04/2018 Last updated: 26/06/2019



## Administrative details

#### PURI

https://redirect.ema.europa.eu/resource/30274

#### **EU PAS number**

EUPAS23268

#### **Study ID**

30274

#### DARWIN EU® study

No

### Study countries

United States

#### **Study description**

The rate of GI bleeding in the 2013 US Medicare hemodialysis population was 23 per 1,000 patien-years (PYs), while the mortality rate from GI bleeding was 0.91 per 1,000 PYs. In placebo-controlled trials, the rate of GI bleeding in hemodialysis patients was similar in the etelcalcetide group (2.0%) and the placebo group (2.1%). We will conduct an observational study to address the possibility of a potential association between calcimimetics and fatal and non-fatal GI bleeding in a population of hemodialysis patients.

#### **Study status**

Finalised

# Research institutions and networks

### Institutions

### Amgen

United States

First published: 01/02/2024

Last updated: 21/02/2024



## Contact details

## Study institution contact Global Development Leader Amgen Inc.

Study contact

medinfo@amgen.com

#### Primary lead investigator

Global Development Leader Amgen Inc.

Primary lead investigator

# Study timelines

#### **Date when funding contract was signed** Planned: 26/10/2017

Actual: 14/03/2018

### Study start date

Planned: 01/05/2018 Actual: 01/05/2018

### Data analysis start date Planned: 01/09/2018

Actual: 01/09/2018

#### Date of final study report Planned: 30/06/2019 Actual: 24/06/2019

## Sources of funding

• Pharmaceutical company and other private sector

## More details on funding

Amgen, Inc.

# Study protocol

EUPAS23268-23566.pdf(433.84 KB)

# Regulatory

#### Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

## Methodological aspects

## Study type

## Study type list

#### **Study topic:**

Human medicinal product Disease /health condition

#### Study type:

Non-interventional study

#### Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

#### Data collection methods:

Secondary use of data

#### Main study objective:

1: Estimate the association between exposure to cinacalcet and the risk of hospitalization from GI bleeding, by region and overall.2. Estimate the association between exposure to cinacalcet and the risk of death from GI bleeding, by region and overall.3: Estimate the rate of hospitalization from GI bleeding and the rate of death from GI bleeding, by region and overall.

# Study Design

#### Non-interventional study design

Cohort

# Study drug and medical condition

### Name of medicine MIMPARA

### **Study drug International non-proprietary name (INN) or common name** CINACALCET HYDROCHLORIDE

#### Anatomical Therapeutic Chemical (ATC) code

(H05BX01) cinacalcet cinacalcet

#### Medical condition to be studied

Gastrointestinal haemorrhage

# **Population studied**

#### Short description of the study population

Patients aged  $\geq$ 18 years who had received in-center hemodialysis at a Dialysis Outcomes and Practice Patterns Study (DOPPS) facility.

#### Age groups

Adults (18 to < 46 years) Adults (46 to < 65 years) Adults (65 to < 75 years) Adults (75 to < 85 years) Adults (85 years and over)

#### Special population of interest

Renal impaired

#### Estimated number of subjects

10000

# Study design details

#### Outcomes

GI bleeding in a hospital setting and death from GI bleeding

#### Data analysis plan

Descriptive statistics using mean and standard deviation (SD) or median and 25th/75th percentile estimates for continuous variables (as appropriate) and number and percentages (n, %) for categorical variables will be used to examine patient characteristics in a cohort of subjects with SHPT who are on dialysis.We will estimate the hazard ratio (HR) and 95% CI for the association of cinacalcet exposure and risk of an inpatient hospitalization for GI bleeding (or death from GI bleeding), implemented using conditional logistic regression analysis for standard matched case-control studies.We will estimate the crude incidence rates of hospitalization for GI bleeding or crude death rates from GI bleeding and associated 95% CIs using the Poisson model.

### Documents

#### **Study results**

20170665\_Observational Research Study Report - Cinacalcet Use and the Risk of Gastrointestinal Bleeding abstract.pdf(154.41 KB)

### Data management

### Data sources

#### Data sources (types)

Disease registry

## Use of a Common Data Model (CDM)

#### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

#### **Check stability**

Unknown

#### **Check logical consistency**

Unknown

## Data characterisation

#### Data characterisation conducted

No